Breast cancer prevention and risk reduction
Research activity includes women at elevated risk of breast cancer, including carriers of pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C, and RAD51D, as well as women with risk assessed through established predictive models and those with prior breast intraepithelial neoplasia.
- Low-dose tamoxifen
- Lifestyle intervention and dietary modification
- Breast cancer risk assessment
The clinical focus extends to symptom-linked prevention strategies and hormonal risk modulation in women under surveillance for hereditary or acquired breast cancer risk.
Advanced breast cancer and metastatic disease
The sponsor is engaged in studies of metastatic breast cancer, including hormone receptor-positive/HER2-negative disease, triple-negative breast cancer, and inflammatory breast cancer with chest wall spread, with attention to disease control in heavily pretreated settings.
- Endocrine-based therapy
- Immunotherapy
- Metronomic chemotherapy
Research also includes treatment selection guided by tumor biology and molecular profiling in advanced breast malignancy.
Breast imaging and diagnostic evaluation
Clinical research covers diagnostic assessment of breast lesions and refinement of imaging pathways in suspected or confirmed breast malignancy, with emphasis on improving specificity in the diagnostic workup.
- Contrast-enhanced spectral mammography
- Breast lesion characterization
- Diagnostic imaging
These activities support earlier and more precise evaluation of breast abnormalities within a specialized oncology setting.
Neuroendocrine neoplasms
The portfolio includes patients with well differentiated neuroendocrine neoplasia who are not eligible for active antitumoral treatment because of clinical frailty or comorbidity, reflecting interest in disease management for vulnerable oncology populations.
- Neuroendocrine tumors
- Frailty-related oncology care
- Supportive treatment strategies
This area addresses care needs in indolent but clinically complex neuroendocrine disease.
Genitourinary syndrome in breast cancer survivors
Research also addresses vulvovaginal and urinary symptoms in postmenopausal women with a history of breast cancer or receiving anti-oestrogen therapy, with attention to quality-of-life concerns in survivorship.
- Prasterone
- Vaginal symptoms
- Urinary discomfort
These studies focus on symptom relief in women affected by endocrine treatment or prior breast cancer.
